CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 29, 2026, 1:21 PM EST
CNBX Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| - | - | 0.13 | 0.41 | 0.03 | - | |
Revenue Growth | - | - | -68.29% | 1269.13% | 318.58% | - |
Gross Profit | - | - | 0.13 | 0.41 | 0.03 | - |
Selling, General & Admin | 0.43 | 0.27 | 0.52 | 0.91 | 1.8 | 0.83 |
Research & Development | - | - | 0.19 | 0.43 | 1.18 | 1.77 |
Operating Expenses | 0.43 | 0.27 | 0.71 | 1.34 | 2.98 | 2.6 |
Operating Income | -0.43 | -0.27 | -0.58 | -0.93 | -2.95 | -2.6 |
Interest Expense | -0.03 | -0.04 | -0.02 | -0 | -0 | -0 |
Currency Exchange Gain (Loss) | -0 | -0 | -0 | 0 | -0.06 | -0.02 |
Other Non Operating Income (Expenses) | - | - | - | -0.05 | -0.72 | -0.96 |
EBT Excluding Unusual Items | -0.46 | -0.31 | -0.61 | -0.98 | -3.74 | -3.59 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.2 |
Gain (Loss) on Sale of Assets | - | - | -0.09 | -2.73 | 0.01 | 0.2 |
Pretax Income | -0.46 | -0.31 | -0.7 | -3.71 | -3.72 | -3.19 |
Net Income | -0.46 | -0.31 | -0.7 | -3.71 | -3.72 | -3.19 |
Net Income to Common | -0.46 | -0.31 | -0.7 | -3.71 | -3.72 | -3.19 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 811 | 91 | 30 | 9 | 1 | 1 |
Shares Outstanding (Diluted) | 811 | 91 | 30 | 9 | 1 | 1 |
Shares Change | 2258.06% | 199.69% | 242.76% | 621.77% | 5.92% | 2.95% |
EPS (Basic) | -0.00 | -0.00 | -0.02 | -0.42 | -3.05 | -2.77 |
EPS (Diluted) | -0.00 | -0.00 | -0.02 | -0.42 | -3.05 | -2.77 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Free Cash Flow | -0.15 | -0.17 | -0.25 | -0.11 | -1.68 | -2.49 |
Free Cash Flow Per Share | - | -0.00 | -0.01 | -0.01 | -1.38 | -2.16 |
Gross Margin | - | - | 100.00% | 100.00% | 100.00% | - |
Operating Margin | - | - | -448.31% | -227.07% | -9860.37% | - |
Profit Margin | - | - | -534.46% | -904.57% | -12428.23% | - |
Free Cash Flow Margin | - | - | -188.71% | -27.43% | -5610.68% | - |
EBITDA | - | -0.2 | -0.51 | -0.77 | -2.76 | -2.38 |
EBITDA Margin | - | - | - | -187.56% | - | - |
D&A For EBITDA | - | 0.07 | 0.07 | 0.16 | 0.2 | 0.22 |
EBIT | -0.43 | -0.27 | -0.58 | -0.93 | -2.95 | -2.6 |
EBIT Margin | - | - | - | -227.07% | - | - |